MN-001 (Tipelukast) - (NATG-202)

June 30, 2026: MediciNova, Inc. (NASDAQ: MNOV; TSE: 4875) provided a corporate update highlighting upcoming clinical catalysts and recent IP progress.

MN-001 (tipelukast): The company completed last patient last visit in its Phase 2 MN-001-NATG-202 multicenter, randomized, double-blind, placebo-controlled trial in hypertriglyceridemia and NAFLD associated with type 2 diabetes. Top-line/initial data are expected in 3Q 2026.

MN-166 (ibudilast): In the SEANOBI expanded-access program in ALS (NCT 06743776), 12 U.S. sites have been activated and 100 patients enrolled (50% of planned 200). The company also cited an “end of 2026” key catalyst: topline data from its COMBAT ALS Phase 2b/3 registration trial.

IP/Preclinical: MediciNova received a USPTO Notice of Allowance for a patent covering ibudilast in combination with an anti-PD-1 antibody for glioblastoma, expected to expire no earlier than September 2042. It also cited a March 2026 Cancer Research publication describing preclinical data suggesting ibudilast can block MIF–CD74 signaling and suppress brain metastasis growth in model systems.